Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26+ leukemia stem cells

Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26+ leukemia stem cells

Introduction: In chronic myeloid leukemia (CML), about half of the patients achieving a deep and stable molecular response with tyrosine kinase inhibitors (TKIs) may discontinue TKI treatment without disease recurrence. As such, treatment-free remission (TFR) has become an ambitious goal of treatmen...

Full description

Bibliographic Details
Main Authors: Paola Pacelli, Adele Santoni, Anna Sicuranza, Elisabetta Abruzzese, Valentina Giai, Monica Crugnola, Mario Annunziata, Sara Galimberti, Alessandra Iurlo, Luigiana Luciano, Federica Sorà, Carmen Fava, Elena Bestoso, Cristina Marzano, Alessandra Cartocci, Marzia Defina, Vincenzo Sammartano, Emanuele Cencini, Donatella Raspadori, Monica Bocchia
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Pharmacology
Subjects:
chronic myelogenous leukemia
treatment free remission
CD26+
leukemia stem cell
TKI
flow cytometry
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1194712/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1194712/full

Similar Items